NVS – Novartis AG

NVS — Price & Float Short

—— Fair value ★ EPS beat ★ EPS miss —— Target Price

Float Short %

0.25

Margin Of Safety %

-2

Put/Call OI Ratio

2.64

EPS Next Q Diff

0.17

EPS Last/This Y

1.68

EPS This/Next Y

1.07

Price

150.46

Target Price

155.66

Analyst Recom

2.57

Performance Q

-8.22

Upside

2.7%

Beta

0.47

Ticker: NVS

22 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-04-21	NVS	147.94	1.89	1.23	60750
2026-04-22	NVS	147.37	1.88	0.39	61405
2026-04-23	NVS	147.52	1.84	7.05	62054
2026-04-24	NVS	145.42	1.87	0.93	62634
2026-04-27	NVS	144.22	1.87	4.18	62632
2026-04-28	NVS	145.53	1.92	3.48	64879
2026-04-29	NVS	142.96	1.95	26.09	68038
2026-04-30	NVS	147.87	2.13	6.51	72631
2026-05-01	NVS	146.55	2.17	0.64	73771
2026-05-04	NVS	144.67	2.17	1.27	73786
2026-05-05	NVS	145.49	2.17	0.65	73814
2026-05-06	NVS	148.34	2.18	1.23	73961
2026-05-07	NVS	145.37	2.17	0.36	75249
2026-05-08	NVS	146.1	2.14	0.56	75602
2026-05-11	NVS	145.19	2.14	5.35	75690
2026-05-12	NVS	148.17	2.17	0.33	76343
2026-05-13	NVS	149.76	2.17	2.29	76410
2026-05-14	NVS	149.79	2.15	12.07	76897
2026-05-15	NVS	148.06	2.23	16.87	79355
2026-05-18	NVS	149.15	2.75	0.26	79176
2026-05-19	NVS	150.52	2.71	0.10	79427
2026-05-20	NVS	150.48	2.64	1.37	80021
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

22 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-04-21	NVS	147.95	-8.9	2652.3	8.87
2026-04-22	NVS	147.37	-8.9	2789.1	8.87
2026-04-23	NVS	147.51	-9.4	2941.7	8.87
2026-04-24	NVS	145.41	-9.4	2661.7	8.87
2026-04-27	NVS	144.20	-9.4	2959.4	8.87
2026-04-28	NVS	145.48	-9.4	3071.2	8.87
2026-04-30	NVS	147.87	-9.4	4168.1	8.87
2026-05-01	NVS	146.61	-12.7	3604.4	9.01
2026-05-04	NVS	144.62	-12.7	3359.4	9.01
2026-05-05	NVS	145.49	-12.7	3632.7	8.96
2026-05-06	NVS	148.29	-12.7	3870.7	8.96
2026-05-07	NVS	145.37	-12.7	3098.6	8.96
2026-05-08	NVS	146.04	-12.7	3485.7	8.96
2026-05-11	NVS	145.21	-12.7	3410.4	8.96
2026-05-12	NVS	148.16	-12.7	3657.0	8.89
2026-05-13	NVS	149.75	-12.7	3513.8	8.89
2026-05-14	NVS	149.83	-12.7	3443.8	8.89
2026-05-15	NVS	148.11	-12.7	3112.3	8.89
2026-05-18	NVS	149.16	-12.7	3276.4	8.89
2026-05-19	NVS	150.49	-12.7	3305.0	8.89
2026-05-20	NVS	150.46	-12.7	3116.5	8.89
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

22 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-04-21	NVS	0	0.02	0
2026-04-22	NVS	0	0.02	0
2026-04-23	NVS	0	0.02	0.34
2026-04-24	NVS	0.00	0.02	0.34
2026-04-27	NVS	0.00	-0.03	0.32
2026-04-28	NVS	0.00	-0.03	0.32
2026-04-29	NVS	0.00	-0.03	0.32
2026-04-30	NVS	0.00	-0.03	0.32
2026-05-01	NVS	0.00	-0.03	0.32
2026-05-04	NVS	0.00	0.02	0.32
2026-05-05	NVS	0.00	0.02	0.32
2026-05-06	NVS	0.00	0.02	0.32
2026-05-07	NVS	0.00	0.02	0.32
2026-05-08	NVS	0.00	0.02	0.32
2026-05-11	NVS	0.00	0.42	0.32
2026-05-12	NVS	0.00	0.42	0.25
2026-05-13	NVS	0.00	0.42	0.25
2026-05-14	NVS	0.00	0.42	0.25
2026-05-15	NVS	0.00	0.42	0.25
2026-05-18	NVS	0.00	0.77	0.25
2026-05-19	NVS	0.00	0.77	0.25
2026-05-20	NVS	0.00	0.77	0.25
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

22 items 1 of 1

Last Quarter Act. EPS

1.99

Avg. EPS Est. Current Quarter

2.11

Avg. EPS Est. Next Quarter

2.16

Insider Transactions

Institutional Transactions

0.77

Beta

0.47

Average Sales Estimate Current Quarter

14229

Average Sales Estimate Next Quarter

14618

Fair Value

147.71

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

11.7

Max Drawdown 5-Year %

-20.4

Target Price

155.66

P/E

21.44

Forward P/E

15.59

PEG

2.51

P/S

5.04

P/B

7.45

P/Free Cash Flow

15.61

EPS

7.02

Average EPS Est. Cur. Y

8.89

EPS Next Y. (Est.)

9.95

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

24.89

Relative Volume

0.7

Return on Equity vs Sector %

8.2

Return on Equity vs Industry %

-2

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

-0.04

EBIT Estimation

3116.5

◆ NVS Healthcare

$150.45

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

13/25

Volume

9/15

Valuation

8/20

TP/AR

2/10

Options

1/10

RSI

54.3

Range 1M

92.4%

Sup Dist

0.7%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

4/25

Growth

3/30

Estimates

8/20

Inst/Vol

4/15

Options

2/10

EPS Yr

-3.5%

EPS NY

11.4%

52W%

67.3%

💎

Long-Term Value

Quality companies, undervalued

WEAK

🟡 HOLD +22.9% upside

Quality

27/30

Valuation

8/30

Growth

4/25

Stability

2/10

LT Trend

2/5

Upside

+22.9%

Quality

MoS

-2%

Novartis AG

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 75267

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

NVS

Latest News

—

Caricamento notizie per NVS…

stock quote shares NVS – Novartis AG Stock Price stock today

news today NVS – Novartis AG stock forecast ,stock prediction 2023 2024 2025

marketwatch NVS – Novartis AG yahoo finance google finance

stock history NVS – Novartis AG invest stock market

stock prices NVS premarket after hours

ticker NVS fair value insiders trading

NVS – Novartis AG

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: NVS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y